Abstract
No public abstract is available from the verified source records.
Sachin V. Pasricha, Jian Roushani, Sheldon W. Tobe
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Time in target range for hemoglobin A1c and systolic blood pressure: association with adverse kidney events
2026
Effects of intensive glucose lowering in type 2 diabetes
10.1056/nejmoa0802743 · 2008
Effects of intensive blood-pressure control in type 2 diabetes mellitus
10.1056/nejmoa1001286 · 2010
Diabetic kidney disease
2015
Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis
10.1001/jama.2014.18574 · 2015
Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency
10.1053/j.ajkd.2019.06.009 · 2020
Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes consensus conference
10.1093/ckj/sfaa123 · 2020
Increased hemoglobin A(1c) time in range reduces adverse health outcomes in older adults with diabetes
10.2337/dc21-0292 · 2021
Long-term visit-to-visit variability in hemoglobin A(1c) and kidney-related outcomes in persons with diabetes
10.1053/j.ajkd.2023.03.007 · 2023
Integrating essence of “time” for blood pressure control in nephrology care
10.1016/j.kint.2024.01.019 · 2024
Systolic blood pressure time in target range and major adverse kidney and cardiovascular events
10.1161/hypertensionaha.122.20141 · 2023
Findings from the KNOW-CKD Study indicate that higher systolic blood pressure time in target range is associated with a lower risk of chronic kidney disease progression
10.1016/j.kint.2023.12.008 · 2024
Time in target range: the future of assessing adequacy of blood pressure control?
10.1161/hypertensionaha.122.20355 · 2023
Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care
10.1503/cmaj.241770 · 2025
Hypertension treatment and control in Canadians with diabetes
10.1016/j.jcjd.2025.05.007 · 2025
Validation of time in range as an outcome measure for diabetes clinical trials
10.2337/dc18-1444 · 2019
No additional external references are available.